Equibles does not estimate personal net worth.
Get an email with a short summary when Amneal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMRX alertsTasos Konidaris is recorded as CFO at Amneal Pharmaceuticals, Inc. (AMRX). Tasos Konidaris has spoken on 20 earnings calls across 1 company, most recently for Amneal Pharmaceuticals, Inc. on November 3, 2026. Amneal Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amneal Pharmaceuticals, Inc. includes Chintu Patel (CEO and Board Member), Chirag Patel (CEO and Board Member), Paul Meister (Chairman and Board Member) and 7 others.
“I'm very pleased to share our third quarter exceptional financial results, which are a testament to our strategic choices and strength of execution. Revenue of $863 million increased 10 percent, adjusted EBITDA of $207 million increased 30 percent, and adjusted EPS of $0.26 increased 53 percent.”
“The second quarter played out as expected with revenue growth accelerating and growth-based momentum building across our business.”
“Turning to the transaction overview on slide 7, as you can see, we have purposely structured through this deal to balance upfront value and success-based consideration to ensure alignment of interests.”
“It includes a little bit of a kind of getting the market set up for the exciting new launch of Rekia. So I think that's a good run rate.”
“We're very pleased with our second quarter financial performance as the resiliency of our diversified business model, strong growth in our specialty business, and focus on efficiency delivered revenue growth of 3%, adjusted EBITDA growth of 13%, and adjusted EPS growth of 56%.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
